Oxygenta Pharmaceutical Share Price
55.00-0.93 (-1.66%)
-23.29% past 1 Year
SS Organics Ltd is a pharmaceutical company involved in the manufacture and marketing of bulk drugs and intermediates.A wide range of new generation quinolones antiasthmatic antiulcerant and anti-inflammatory drugs are
Corporate filings & documents
Announcements
Disclosure under Regulation 44(3) of SEBI (LODR) Regulations 2015.
1 week agoDisclosure under Regulation 44(3) of SEBI (LODR) Regulations 2015.
1 week agoOutcome of 33rd Annual General Meeting held on 21.08.2026.
2 weeks agoOutcome of 33rd Annual General Meeting held on 21.08.2026.
2 weeks agoNewspaper Advertisement for Notice of AGM scheduled to be held on 21st August 2026.
1 month agoNewspaper Advertisement for Notice of AGM scheduled to be held on 21st August 2026.
1 month agoIntimation of Book Closure and Cut-off Date for the AGM
1 month agoIntimation of Book Closure and Cut-off Date for the AGM
1 month agoSubmission of 33rd Annual Report for the Financial Year 2025-26 under Regulation 34 of SEBI (LODR) Regulations 2015
1 month agoSubmission of 33rd Annual Report for the Financial Year 2025-26 under Regulation 34 of SEBI (LODR) Regulations 2015
1 month agoNotice of 33rd Annual General Meeting for the Financial Year 2025-26.
1 month agoNotice of 33rd Annual General Meeting for the Financial Year 2025-26.
1 month agoAppointment of Cost Auditor for the Financial Year 2026-27.
1 month agoAppointment of Cost Auditor for the Financial Year 2026-27.
1 month agoUn-audited Financial Results for the Quarter ended 30.06.2026.
1 month agoUn-audited Financial Results for the Quarter ended 30.06.2026.
1 month agoUn-audited Financial results for the Quarter ended 30.06.2026.
1 month agoUn-audited Financial results for the Quarter ended 30.06.2026.
1 month agoThe Board Meeting to be held on 25/07/2026 has been revised to 27/07/2026 Postponement of the Board Meeting to be held on Saturday 25th July 2026 and rescheduling of the board meeting to 27th July 2026.
1 month agoThe Board Meeting to be held on 25/07/2026 has been revised to 27/07/2026 Postponement of the Board Meeting to be held on Saturday 25th July 2026 and rescheduling of the board meeting to 27th July 2026.
1 month agoOxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/07/2026 inter alia to consider and approve 1. Unaudited Financial Results for the quarter ended 30.06.20262. Any other item with the permission of chair
1 month agoOxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/07/2026 inter alia to consider and approve 1. Unaudited Financial Results for the quarter ended 30.06.20262. Any other item with the permission of chair
1 month agoCompliance as per Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended 30th June 2026.
1 month agoCompliance as per Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended 30th June 2026.
1 month agoClosure of trading window for the period ending 30.06.2026.
2 months agoClosure of trading window for the period ending 30.06.2026.
2 months agoAnnual Secretarial Compliance Report for the year ended 31.03.2026 pursuant to Regulation 24A of SEBI (LODR) Regulations 2018.
3 months agoAnnual Secretarial Compliance Report for the year ended 31.03.2026 pursuant to Regulation 24A of SEBI (LODR) Regulations 2018.
3 months agoChange in Management by way of appointment of Additional Directors and Internal Auditor.
3 months agoChange in Management by way of appointment of Additional Directors and Internal Auditor.
3 months agoAudited Financial Results for the Quarter and Year ended 31.03.2026.
3 months agoAudited Financial Results for the Quarter and Year ended 31.03.2026.
3 months agoOutcome of the Board meeting held on 23rd May 2026.
3 months agoOutcome of the Board meeting held on 23rd May 2026.
3 months agoOxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2026 inter alia to consider and approve 1. Audited Financial Results for the quarter and year ended 31.03.20262. Audit Report for the year ended 31.03.20263. Any other item with the permission of chair
3 months agoOxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2026 inter alia to consider and approve 1. Audited Financial Results for the quarter and year ended 31.03.20262. Audit Report for the year ended 31.03.20263. Any other item with the permission of chair
3 months ago<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Oxygenta Pharmaceutical Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L24110TG1990PLC012038</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>FY 2025-26 2026-27</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>NIL</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>NIL</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>NIL</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>FY 2025-26 2024-25</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>KUMKUM BAJAJ</td></tr><tr><td>Designation :-</td><td>COMPANY SECRETARY AND COMPLIANCE OFFICER</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>PRASAD REDDY BATTINAPATLA</td></tr> <tr><td>Designation : -</td><td>CHIEF FINANCIAL OFFICER</td></tr></table><div> <br/> Date: 27/04/2026<br/><br/></div>
4 months ago<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Oxygenta Pharmaceutical Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L24110TG1990PLC012038</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>FY 2025-26 2026-27</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>NIL</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>NIL</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>NIL</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>FY 2025-26 2024-25</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>KUMKUM BAJAJ</td></tr><tr><td>Designation :-</td><td>COMPANY SECRETARY AND COMPLIANCE OFFICER</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>PRASAD REDDY BATTINAPATLA</td></tr> <tr><td>Designation : -</td><td>CHIEF FINANCIAL OFFICER</td></tr></table><div> <br/> Date: 27/04/2026<br/><br/></div>
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Oxygenta Pharmaceutical Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24110TG1990PLC012038</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>1073089940.31</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NIL</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: KUMKUM BAJAJ <br/> Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: PRASAD REDDY BATTINAPATLA <br/> Designation: CHIEF FINANCIAL OFFICER <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 27/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months agoCompliance as per Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the Quarter ended 31st March 2026
4 months agoClosure of Trading Window for the period ending on 31.03.2026.
5 months agoClosure of Trading Window for the period ending on 31.03.2026.
5 months agoDisclosure under Regulation 30 of SEBI (Listing Obligations and Discloure Requirements) Regulations 2015.
6 months agoDisclosure under Regulation 30 of SEBI (Listing Obligations and Discloure Requirements) Regulations 2015.
6 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Virupaksha Organics Ltd
6 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Virupaksha Organics Ltd
6 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Virupaksha Organics Ltd
6 months agoUn-audited Results for the Quarter and nine months ended 31.12.2025.
7 months agoWith reference to the subject cited this is to inform the Exchange that the Board of Directors of Oxygenta Pharmaceutical Limited at its Meeting held on Wednesday 04th February 2026 at 12:00 noon at the corporate office of the Company considered and approved the following:1. Un-audited Financial Results for the quarter and nine months ended 31.12.2025. (Attached as Annexure)2. Limited Review Report for the quarter and nine months ended 31.12.2025. (Attached as Annexure)3. Re-constitution of Internal Complaints Committee (ICC) constituted under The Sexual Harassment of Women at Workplace (Prevention Prohibition and Redressal) Act 2013 (POSH Act) w.e.f. 04.02.2026. (Attached as Annexure -I)
7 months agoOxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2026 inter alia to consider and approve 1. Un-audited Financial results for the quarter ended December 31 2025.2. Limited Review Report for the quarter ended December 31 2025.3. Any other business with the permission of the Chair.
7 months agoAnnual reports
Concalls & investor presentations
No presentations found
Corporate Actions
Date
Type
Details
No data available.
Company details
Registered office
Survey No. 252/1 Aroor Village Sadasivapet Mandal Sangareddy Telangana PIN: 502291 Tel No: 08455-250080 Fax No: 08465 250090 Email: [email protected] / [email protected] Internet: www.oxygentapharma.com
Registrars
Aurum, Door No 4-50/P-II/57/4F&5F Plot No 57, 4th & 5th Floors, Jayabheri Enclave Phase - II, Gachibowli(Old Address:12-10-167, MIG- 167,Bharat Nagar Colony, Hyderabad – 500018.)Phone: +91-40-23818475/6Fax : +91-40-23868024Email: info@vccili Aurum, Door No 4-50/P-II/57/4F&5F Plot No 57 4th & 5th Floors Jayabheri Enclave Phase - II, Gachibowli PIN: Tel No: 23818475,23868257,35164910 Fax No: NULL Email: [email protected] Internet: www.vccipl.com
Management
Balasubba Reddy Mamilla, Whole Time Director
Chandra Mouliswar Reddy Gangavaram, Whole Time Director
Sidda Reddy Kanuparthi, Non Executive Independent Director
Veera Reddy Arava, Non Executive Independent Director
Sharvari Swapnil Shinde, Non Executive Independent Director
Janardhana Reddy Yeddula, Non Executive Independent Director
Vedavathi Gangavaram, Non Independent & Non Executive Director
Kumkum Bajaj, Company Secretary & Compliance Officer
Amireddy Venkatesu Reddy, Whole Time Director
Details
BSE 524636
NSE NULL
ISIN INE102E01018